[ad_1]
AstraZeneca, a science-led biopharmaceutical company and one of the top 10 biopharmaceutical companies in the world, has signed a strategic partnership agreement with artificial intelligence-driven healthcare company G42 Healthcare to locally manufacture innovative drugs in Abu Dhabi.
The binding agreement focuses on cooperation in four key areas, including localization of innovative industries, research and development, innovation and sustainable development on a global scale.
The agreement builds on the continued efforts of the Abu Dhabi Department of Health (DoH) to lead Abu Dhabi’s healthcare ecosystem, strengthening the emirate’s position as a center for life sciences research and innovation.
This is the latest in a series of long-term partnerships with key players in the pharmaceutical industry.
The agreement was signed by G42 Healthcare CEO Ashish Koshy and AstraZeneca Middle East and Africa Vice President Pelin Incesu in the presence of DoH Chairman Abdulla bin Mohammed Al Hamed, Executive Director and CEO Pascal Soriot AstraZeneca Executive, Health Dr. Jamal Mohammed Al Kaabi, Undersecretary of Ministry and Peng Xiao, CEO of G42 Group.
It is in line with the National Industrial and Advanced Technology Strategy and the Make it in the Emirates initiative launched by the Ministry of Industry and Advanced Technology to enhance the UAE’s business environment and status as an attractive destination for investors in local and global industries , G42 Healthcare said in a statement.
It also supports the growth and competitiveness of national industries, the innovation and adoption of advanced technologies, and the UAE’s position as a global hub for future industries.
The partnership factor in Abu Dhabi’s industrial strategy to double the size of the manufacturing sector by 2031.
In essence, the agreement will expand Abu Dhabi’s footprint in life sciences research and development and foster innovation across all healthcare sectors, it said.
All parties will work closely together to boost exports and develop cutting-edge science and activities to support the delivery of life-changing medicines to Emirati patients. It added that based on international best practice, the partnership aims to develop sustainable solutions for healthcare transformation while achieving a balance between economic growth and sustainability.
Commenting on the agreement, Sameh ElFangary, AstraZeneca GCC and Pakistan Cluster President, said: “We are honored to be a long-term, trusted partner in the UAE, bringing innovative healthcare to the region, and we have a strong interest in Abu Dhabi as a regional healthcare provider. Appreciation of the Center’s ambitions for the Life Sciences Center.”
“We are now taking our comprehensive existing partnership with G42 Healthcare to new heights, accelerating collaboration on local manufacturing, research, innovation and sustainable development,” he noted.
Dr Al Kaabi said the localization and manufacturing of medicines in Abu Dhabi is a true reflection of our ‘Made in UAE’ movement – a cornerstone of sustainable development in all industries.
“Abu Dhabi continues to see international appetite and investment opportunities across the biopharmaceutical and healthcare value chain due to the industry’s strong growth potential. Research in all its forms remains a core driver of all our ambitions as we continue to build upon Abu Dhabi’s position as a leader in innovative healthcare and life sciences,” he noted.
The partnership further establishes Abu Dhabi as a medical research and innovation powerhouse on the international stage.
In 2021, the emirate’s capacity to develop scientific and clinical research has doubled – with more research projects in the year than in the previous five years. Today, more than 400 clinical research trials are underway in the UAE.
Koshy said: “At G42 Healthcare, we are confident in the potential of our continued partnership with AstraZeneca, which has a strong commitment to the UAE healthcare industry and is poised to become a global hub for life sciences research and innovation.”
“This strategic collaboration will accelerate innovation in local manufacturing and allow us to explore greater possibilities for clinical research to bring life-changing treatments to patients in the UAE and across the region. At the heart of this partnership is our ability to promote The willingness to sustain manufacturing and drive innovation at a global level as we collectively envision better healthcare for all,” he added.
Copyright 2022 Al Hilal Publishing and Marketing Group Courtesy of SyndiGate Media Inc. (Syndicate Information).
[ad_2]
Source link